DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-010955-29-NL (EUCTR)	13/07/2009	27/02/2009	Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.	Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.	Pre-clinical RA patients with a high risk on developing the disease.	Trade Name: MabThera 500 mg (10mg/ml) INN or Proposed INN: Rituximab	Division of Clinically Immunology and Rheumatology, AMC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

13/07/2009

27/02/2009

Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.

Pre-clinical RA patients with a high risk on developing the disease.

Trade Name: MabThera 500 mg (10mg/ml)
INN or Proposed INN: Rituximab

Division of Clinically Immunology and Rheumatology, AMC

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Netherlands